OncoC4 Secures $50 Million in Series B Funding for Cancer Therapy Development

Oct 3, 2025
OncoC4, a biotechnology company, has closed a Series B financing round of nearly $50 million to advance its pipeline of cancer therapies, announced in a press release.

OncoC4 has closed a Series B financing round of nearly $50 million, announced in a press release. The round was led by GBA Fund, with participation from the company's co-founders and existing investors, including HM Capital, 3E Bioventures Capital, and Kaitai Capital.

Founded in 2020 by immunologists Dr. Yang Liu and Dr. Pan Zheng, OncoC4 is focused on developing innovative therapies for cancer and neurodegenerative diseases. The funds from this financing round will be used to advance the clinical development of the company's pipeline programs, which target both novel and well-validated targets across oncology and immunological diseases.

Dr. Yang Liu, Co-Founder and CEO of OncoC4, expressed gratitude for the investors' support and emphasized the company's commitment to advancing its core pipeline and expanding business development activities globally.

We hope you enjoyed this article

Free newsletter

AI Funding Brief

AI Token Webinar

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.